Tacrolimus-associated hemolytic uremic syndrome: A case analysis

Journal of Nephrology

Volumn 16, Issue 4, 2003, Pages 580-585

  Lin, Chih Ching ^a,b   King, Kuang Liang ^a,b   Chao, Yu Wen ^a,b   Yang, An Han ^a,b   Chang, Chao Fu ^a,b   Yang, Wu Chang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Hemolytic uremic syndrome; Renal transplantation; Tacrolimus; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CEFUROXIME; CREATININE; CYCLOSPORIN A; GANCICLOVIR; LACTATE DEHYDROGENASE; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TEICOPLANIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEATH; DIALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DYSFUNCTION; MALE; MORBIDITY; MORTALITY; PATIENT MONITORING; PLASMAPHERESIS; POSTOPERATIVE INFECTION; PREDICTION; PREVALENCE; PROGNOSIS; RECIPIENT; RISK FACTOR; THROMBOCYTE COUNT;

ADULT; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; POSTOPERATIVE COMPLICATIONS; REOPERATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; TACROLIMUS; TREATMENT OUTCOME;

EID: 1642558366     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Shulman H, Striker G, Deeg HG. Nephrotoxicity of cyclosporin A after allogenic bone marrow transplantation. New Engl J Med 1981; 305: 1392-5.
2. Schmidt R, Venkat K, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK506 immunosuppression. Transplant Proc 1991; 23: 3156.
3. Ichihashi T, Naoe T, Yoshida H. Hemolytic uremic syndrome during FK506 therapy. Lancet 1992; 340: 60-1.
4. Holman MJ, Gonwa TA, Cooper B. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55: 205-6.
5. Gharpure VS, Devine SM, Holland HK. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 715-6.
6. Mach-Pascual S, Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996; 52: 310-2.
7. Randhawa P, Tsamandas A, Magnone M. Microvascular changes in renal allografts associated with FK506 (tracolimus) therapy. Am J Surg Pathol 1996; 20: 306-12.
8. Walder B, Ricou B, Suter PM. Tacrolimus (FK506)-induced hemolytic uremic syndrome after heart transplantation. J Heart Lung Transplant 1998; 17: 1004-6.
9. Myers JN, Shabshab SF, Burton NA. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999; 18: 1024-6.
10. Schmidt RH, Lenz T, Grone HJ. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. Nephrol Dial Transplant 1999; 14: 979-83.
11. Trimarchi HM, Truong LD, Brennan S. FK506-associated thrombotic microangiopathy; Report of two cases and review of the literature. Transplantation 1999; 67: 539-44.
12. Rerolle JP, Akposso K, Lerolle N. Tracolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000; 14: 262-5.
13. Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type I in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327: 755-9.
14. Grupp C, Schmidt F, Braun F. Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation - Is tacrolimus the answer? Nephrol Dial Transplant 1998; 13: 1629-31.
15. Ruggenenti P, Lutz J, Remuzzi G. Pathogenesis and treatment of thrombotic microangiopathy. Kidney Int 1997; 58 (suppl XX): S97-101.
16. Brown Z, Neild GH. FK-506 and haemolytic uraemic syndrome. Lancet 1990; 335: 412.
17. Candinas D, Keusch G, Schlumpf R. Prognostic factors of hemolytic uremic syndrome in renal allografts. Transplant Proc 1993; 25: 1041-2.
18. Baid S, Pascual M, William WW Jr. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-53.
19. Wada H, Kaneko T, Ohiwa M. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol 1992; 40: 167-70.
20. Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002; 62: 1093-104.
21. Venkat KK, Tkach D, Kupin W. Reversal of cyclosporine associated hemolytic uremic syndrome by plasma exchange with fresh frozen plasma replacement in renal transplant recipients. Transplant Proc 1991; 23: 1256-7.
22. Agarwal A, Mauer SM, Matas AJ. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management. J Am Soc Nephrol 1995; 6: 1160-9.